The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules

Nature Immunology

Volumn 5, Issue 7, 2004, Pages 685-692

  Watts, Colin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CD4 ANTIGEN; EPITOPE; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEINASE; CHAPERONE; HLA ANTIGEN CLASS 2;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ENDOCYTOSIS; ENDOSOME; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; IMMUNOREGULATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN PROCESSING; REVIEW; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MOLECULAR CHAPERONES;

EID: 3242743087     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1088     Document Type: Review

References (131)

1. Germain, R.N. & Margulies, D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11, 403-450 (1993).
2. Wolf, P.R. & Ploegh, H.L. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu. Rev. Cell Cev. Biol. 11, 267-306 (1995).
3. Cresswell, P. Invariant chain structure and MHC class II function. Cell 84, 505-507 (1996).
4. Watts, C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15, 821-850 (1997).
5. Engelhard, V.H. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12, 181-207 (1994).
6. Hiltbold, E.M. & Roche, P.A. Trafficking of MHC class II molecules in the late secretory pathway. Curr. Opin. Immunol. 14, 30-35 (2002).
7. Lanzavecchia, A., Reid, P.A. & Watts, C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 357, 249-252 (1992).
8. Robinson, J.H. & Delvig, A.A. Diversity in MHC class II antigen presentation. Immunology 105, 252-262 (2002).
9. Bennett, K. et al. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur. J. Immunol. 22, 1519-1524 (1992).
10. Santambrogio, L. et al. Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl. Acad. Sci. USA 96, 15056-15061 (1999).
11. Musson, J.A., Walker, N., Flick-Smith, H., Williamson, E.D. & Robinson, J.H. Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J. Biol. Chem. 278, 52425-52431 (2003).
12. Watts, C. Antigen processing in the endocytic compartment. Curr. Opin. Immunol. 13, 26-31 (2001).
13. Honey, K. & Rudensky, A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3, 472-482 (2003).
14. Bryant, P. & Ploegh, H. Class II MHC peptide loading by the professionals. Curr. Opin. Immunol. 16, 96-102 (2004).
15. Blum, J.S. & Cresswell, P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl. Acad. Sci. USA 85, 3975-3979 (1988).
16. Amigorena, S. et al. Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles. J. Exp. Med. 181, 1729-1741 (1995).
17. Manoury, B. et al. Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. Immunity 18, 489-498 (2003).
18. Riese, R.J. et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4, 357-366 (1996).
19. Brachet, V., Raposo, G., Amigorena, S. & Mellman, I. li chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes. J. Cell. Biol. 137, 51-65 (1997).
20. Driessen, C. et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell. Biol. 147, 775-790 (1999).
21. Nakagawa, T. et al. Cathepsin L: critical role in li degradation and CD4 T cell selection in the thymus. Science 280, 450-453 (1998).
22. Tolosa, E. et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J. Clin. Invest. 112, 517-526 (2003).
23. Bahia, J. et al. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc. Natl. Acad. Sci. USA 100, 6664-6669 (2003).
24. Shi, G.P. et al. Role for cathepsin F in invariant chain processing and major Histocompatibility complex class II peptide loading by macrophages. J. Exp. Med. 191, 1177-1185 (2000).
25. Saegusa, K. et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest. 110, 361-369 (2002).
26. Riese, R.J. et al. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 101, 2351-2363 (1998).
27. Nakagawa, T.Y. et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10, 207-217 (1999).
28. Villadangos, J.A., Riese, R.J., Peters, C., Chapman, H.A. & Ploegh, H.L. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med. 188, 549-560 (1997).
29. Wiendl, H. et al. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J. Neuroimmunol. 138, 132-143 (2003).
30. Matza, D. et al. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc. Natl. Acad. Sci. USA 99, 3018-3023 (2002).
31. Matza, D., Kerem, A. & Shachar, I. Invariant chain, a chain of command. Trends Immunol. 24, 264-268 (2003).
32. Shi, G.P. et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10, 197-206 (1999).
33. Denzin, L.K. & Cresswell, P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 82, 155-165 (1995).
34. Sloan, V.S. et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375, 802-806 (1995).
35. Sherman, M.A., Weber, D.A. & Jensen, P.E. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3, 197-205 (1995).
36. Busch, R. & Mellins, E.D. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr. Opin. Immunol. 8, 51-58 (1996).
37. Kropshofer, H., Hammerling, G.J. & Vogt, A.B. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol. Today 18, 77-82 (1997).
38. Alfonso, C. & Karlsson, L. Nonclassical MHC class II molecules. Annu. Rev. Immunol. 18, 113-142 (2000).
39. Brocke, P., Garbi, N., Momburg, F. & Hammerling, G.J. HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr. Opin. Immunol. 14, 22-29. (2002).
40. Belmares, M.P., Busch, R., Wucherpfennig, K.W., McConnell, H.M. & Mellins, E.D. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J. Immunol. 169, 5109-5117 (2002).
41. Stratikos, E., Wiley, D.C. & Stern, L.J. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain. J. Immunol. 172, 1109-1117 (2004).
42. Pu, Z., Lovitch, S.B., Bikoff, E.K. & Unanue, E.R. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 20, 467-476 (2004).
43. Stebbins, C.C., Loss, G.E., Jr., Elias, C.G., Chervonsky, A. & Sant, A.J. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J. Exp. Med. 181, 223-234 (1995).
44. Wolf, P.R. et al. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur. J. Immunol. 28, 2605-2618 (1998).
45. k class II molecules in human APC containing deleted or mutated HLA DM genes. J. Immunol. 5382-5392 (1994).
46. Koonce, C.H. et al. DM loss in k haplotype mice reveals isotype-specific chaperone requirements. J. Immunol. 170, 3751-3761 (2003).
47. Pashine, A. et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 19, 183-192 (2003).
48. Liljedahl, M. et al. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J. 15, 4817-4824 (1996).
49. Chen, X. et al. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J. Exp. Med. 195, 1053-1062 (2002).
50. Glazier, K.S. et al. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J. Exp. Med. 195, 1063-1069 (2002).
51. Perraudeau, M. et al. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur. J. Immunol. 30, 2871-2880 (2000).
52. Liljedahl, M. et al. Altered antigen presentation in mice lacking H2-O. Immunity 8, 233-243 (1998).
53. van Ham, M. et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J. Exp. Med. 191, 1127-1136 (2000).
54. Watts, C., West, M.A., Reid, P.A. & Davidson, H.W. Processing of immunoglobulin-associated antigen in B lymphocytes. Cold Spring Harb. Symp. Quant. Biol. 1, 345-352 (1989).
55. Brocke, P., Armandola, E., Garbi, N. & Hammerling, G.J. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes. Eur. J. Immunol. 33, 411-421 (2003).
56. Alfonso, C. et al. Analysis of H2-O influence on antigen presentation by B cells. J. Immunol. 171, 2331-2337 (2003).
57. Sercarz, E.E. et al. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729-766 (1993).
58. Driessen, C., Lennon-Dumenil, A.M. & Ploegh, H.L. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcγ receptors. Eur. J. Immunol. 31, 1592-1601 (2001).
59. Pluger, E.B. et al. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur. J. Immunol. 32, 467-476 (2002).
60. Hsieh, C.S., deRoos, P., Honey, K., Beers, C. & Rudensky, A.Y. A Role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J. Immunol. 168, 2618-2625 (2002).
61. + T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J. Exp. Med. 195, 1349-1358 (2002).
62. Manoury, B. et al. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396, 695-699 (1998).
63. Chen, J.M., Rawlings, N.D., Stevens, R.A.E. & Barrett, A.J. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cystein endopeptidases. FEBS Lett. 441, 461-465 (1998).
64. Watts, C. et al. Roles for asparagine endopeptidase in class II MHC-restricted antigen processing. Biochem. Soc. Symp. 70, 31-38 (2003).
65. Antoniou, A.N., Blackwood, S.L., Mazzeo, D. & Watts, C. Control of antigen presentation by a single protease cleavage site. Immunity 12, 391-398 (2000).
66. Loak, K. et al. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase. Biol. Chem. 384, 1239-1246 (2003).
67. Manoury, B. et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat. Immunol. 3, 169-174 (2002).
68. Krogsgaard, M. et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191, 1395-1412. (2000).
69. Brooks, K. & Knight, A.M. Lowering the affinity between antigen and the B cell receptor can enhance antigen presentation. Eur. J. Immunol. 34, 837-843 (2004).
70. Collins, D.S., Unanue, E.R. & Harding, C.V. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J. Immunol. 147, 4054-4059 (1991).
71. Jensen, P.E. Antigen unfolding and disulfide reduction in antigen presenting cells. Semin. Immunol. 7, 347-353 (1995).
72. Arunachalam, B., Phan, U.T., Geuze, H.J. & Cresswell, P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a γ-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. USA 97, 745-50 (2000).
73. Haque, M.A. et al. Absence of γ-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J. Exp. Med. 195, 1267-1277 (2002).
74. Maric, M. et al. Defective antigen processing in GILT-free mice. Science 294, 1361-1365 (2001).
75. Li, P., Haque, M.A. & Blum, J.S. Role of disulfide bonds in regulating antigen processing and epitope selection. J. Immunol. 169, 2444-2450 (2002).
76. Kalka-Moll, W.M. et al. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J. Immunol. 169, 6149-6153 (2002).
77. Cobb, B.A., Wang, Q., Tzianabos, A.O. & Kasper, D.L. Polysaccharide processing and presentation by the MHCII pathway. Cell 117, 677-687 (2004).
78. Shirahama-Noda, K. et al. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J. Biol. Chem. 278, 33194-33199 (2003).
79. Honey, K. et al. Cathepsin S regulates the Expression of cathepsin L and the turnover of γ-interferon-inducible lysosomal thiol reductase in B lymphocytes. J. Biol. Chem. 276, 22573-22578 (2001).
80. Lennon-Dumenil, A.M. et al. The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO J. 20, 4055-4064 (2001).
81. Honey, K. et al. Thymocyte expression of cathepsin L is essential for NKT cell development. Nat. Immunol. 3, 1069-1074 (2002).
82. Guncar, G., Pungercic, G., Klemencic, I., Turk, V. & Turk, D. Crystal structure of MHC class II-associated p41 li fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18, 793-803 (1999).
83. Ogrinc, T., Dolenc, I., Ritonja, A. & Turk, V. Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Lett. 336, 555-559 (1993).
84. Fiebiger, E. et al. Invariant chain controls the activity of extracellular cathepsin L. J. Exp. Med. 196, 1263-1269 (2002).
85. Beers, C., Honey, K., Fink, S., Forbush, K. & Rudensky, A. Differential regulation of cathepsin S and cathepsin L in interferon-γ-treated macrophages. J. Exp. Med. 197, 169-179 (2003).
86. Peterson, M. & Miller, J. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. Nature 357, 596-598 (1992).
87. Fiebiger, E. et al. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J. Exp. Med. 193, 881-892 (2001).
88. Trombetta, E.S., Ebersold, M., Garrett, W., Pypaert, M. & Mellman, I. Activation of lysosomal function during dendritic cell maturation. Science 299, 1400-1403 (2003).
89. Li, D.N., Matthews, S.P., Antoniou, A.N., Mazzeo, D. & Watts, C. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J. Biol. Chem. 278, 38980-38990 (2003).
90. Kleijmeer, M. et al. Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J. Cell. Biol. 155, 53-63 (2001).
91. Chow, A., Toomre, D., Garrett, W. & Mellman, I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 418, 988-994 (2002).
92. Celia, M., Engering, A., Pinet, V., Pieters, J. & Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782-787 (1997).
93. Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351-358 (2002).
94. Veeraswamy, R.K., Celia, M., Colonna, M. & Unanue, E.R. Dendritic cells process and present antigens across a range of maturation states. J. Immunol. 170, 5367-5372 (2003).
95. Wilson, N.S., El-Sukkari, D. & Villadangos, J.A. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103, 2187-2195 (2004).
96. Turley, S.J. et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288, 522-527 (2000).
97. Boes, M. et al. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature 418, 983-988 (2002).
98. + compartments in dendritic cells. J. Immunol. 171, 5689-5696 (2003).
99. Poloso, N.J. & Roche, P.A. Association of MHC class II-peptide complexes with plasma membrane lipid microdomains. Curr. Opin. Immunol. 16, 103-107 (2004).
100. Kropshofer, H. et al. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat. Immunol. 3, 61-68 (2002).
101. Lee, P., Matsueda, G.R. & Allen, P.M. T cell recognition of fibrinogen. A determinant on the A α-chain does not require processing. J. Immunol. 140, 1063-1068 (1988).
102. Davidson, H.W., Reid, P.A., Lanzavecchia, A. & Watts, C. Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific B lymphocytes. Cell 67, 105-116 (1991).
103. Lindner, R. & Unanue, E.R. Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J. 15, 6910-6920 (1996).
104. Villadangos, J.A., Driessen, C., Shi, G.-P., Chapman, H.A. & Ploegh, H.L. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. EMBO J. 19, 882-891 (2000).
105. Nelson, C.A., Vidavsky, I., Viner, N.J., Gross, M.L. & Unanue, E.R. Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 94, 628-633 (1997).
106. Lippolis, J.D. et al. Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J. Immunol. 169, 5089-5097 (2002).
107. Carson, R.T., Vignali, K.M., Woodland, D.L. & Vignali, D.A. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 7, 387-399 (1997).
108. Sercarz, E.E. & Maverakis, E. MHC-guided processing: binding of large antigen fragments. Nat. Rev. Immunol. 3, 621-629 (2003).
109. Joyce, S. & Van Kaer, L. CD1-restricted antigen presentation: an oily matter. Curr. Opin. Immunol. 15, 95-104 (2003).
110. Brigl, M. & Brenner, M.B. CD1: Antigen presentation and T cell function. Annu. Rev. Immunol. 22, 817-90 (2004).
111. + T lymphocytes. Science 268, 863-865 (1995).
112. Gadola, S.D. et al. Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains. Nat. Immunol. 3, 721-726 (2002).
113. Zajonc, D.M., Elsliger, M.A., Teyton, L. & Wilson, I.A. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 Å. Nat. Immunol. 4, 808-815 (2003).
114. Sugita, M. et al. Failure of trafficking and antigen presentation by CD1 in AP-3-deficient cells. Immunity 16, 697-706 (2002).
115. α14i NKT cells. J. Exp. Med. 198, 1133-1146 (2003).
116. Cernadas, M. et al. Lysosomal localization of murine CD1d mediated by AP-3 is necessary for NK T cell development. J. Immunol. 171, 4149-4155 (2003).
117. Moody, D.B. & Porcelli, S.A. CD1 trafficking: invariant chain gives a new twist to the tale. Immunity 15, 861-865 (2001).
118. Kang, S.J. & Cresswell, P. Regulation of intracellular trafficking of human CD1d by association with MHC class II molecules. EMBO J. 21, 1650-1660 (2002).
119. Jayawardena-Wolf, J., Benlagha, K., Chiu, Y.H., Mehr, R. & Bendelac, A. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 15, 897-908 (2001).
120. Chiu, Y.H. et al. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat. Immunol. 3, 55-60 (2002).
121. + T cell selection and maturation by cathepsin S. Immunity 15, 909-919 (2001).
122. Kang, S.J. & Cresswell, P. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5, 175-181 (2004).
123. Zhou, D. et al. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303, 523-527 (2004).
124. Winau, F. et al. Saposin C is required for lipid presentation by human CD1b. Nat. Immunol. 5, 169-174 (2004).
125. Leonova, T. et al. Proteolytic processing patterns of prosaposin in insect and mammalian cells. J. Biol. Chem. 271, 17312-17320 (1996).
126. Vielhaber, G., Hurwitz, R. & Sandhoff, K. Biosynthesis, processing, and targeting of sphingolipid activator protein (SAP) precursor in cultured human fibroblasts. Mannose 6-phosphate receptor-independent endocytosis of SAP precursor. J. Biol. Chem. 271, 32438-32446 (1996).
127. Kyewski, B., Derbinski, J., Gotter, J. & Klein, L. Promiscuous gene expression and central T-cell tolerance: more than meets the eye. Trends Immunol. 23, 364-371 (2002).
128. Anderson, M.S. et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 10, 1395-1401 (2002).
129. Newcomb, J.R. & Cresswell, P. Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo. J. Immunol. 151, 4153-4163 (1993).
130. Denzin, L.K., Hammond, C. & Cresswell, P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184, 2153-2165 (1996).
131. Simitsek, P.D., Campbell, D.G., Lanzavecchia, A., Fairweather, N. & Watts, C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181, 1957-1963 (1995).